Adverse events (12 (12, 26)) · people with congenital heart disease.
1 finding from 1 review
Adverse events · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Short‐term impact (< 12 months) unintended adverse events · children aged 5 years and under
1 finding from 1 review
Unintended adverse events ‐ not reported · children aged 5 years and under
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term impact (< 12 months) unintended adverse events ‐ not reported · children aged 5 years and under
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (Vitamin B6 (pyridoxine;… showed no clear difference in adverse events compared with placebo or standard care (high certainty).
1 finding from 1 review
Adverse events · people at high risk of or withcardiovascular disease
Mindfulness‐based interventions (MBIs) showed no clear difference in adverse events compared with non‐active comparators (low certainty).
1 finding from 1 review
Adverse events · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term impact (< 12 months) unintended adverse events · children aged 5 years and under
1 finding from 1 review
Intervention not reported
Adverse events · adults (age 18 years or over) with myocardial infarction, stable angina, following coronary artery bypass graft surgery or percutaneous…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Adverse events · heart failure in patients with Chagas cardiomyopathy
It is very uncertain whether carvedilol changes adverse events compared with placebo (very low certainty).
1 finding from 1 review